Current options for prophylactic treatment of hereditary angioedema in the United States: Patient-based considerations

Allergy and Asthma Proceedings

Volumn 33, Issue 3, 2012, Pages 235-240

  Gower, Richard G ^a   Lumry, William R ^b   Davis Lorton, Mark A ^c   Johnston, Douglas T ^d   Busse, Paula J ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Winthrop Rheumatology Allergy and Immunology ^*  (United States)

^d EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; CI INH; DANAZOL; FRESH FROZEN PLASMA; OXANDROLONE; STANOZOLOL; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANXIETY; CLINICAL FEATURE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ERYTHEMA; FEVER; HAIR GROWTH; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LABORATORY DIAGNOSIS; LIVER ADENOMA; NAUSEA; PATIENT CARE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PROPHYLAXIS; PRURITUS; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; VIRILIZATION; VOICE; WEIGHT GAIN;

ADULT; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HUMANS; PREMEDICATION; UNITED STATES;

EID: 84862565650     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3573     Document Type: Review

References (24)

1. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25:4292-4301, 1986.
2. Ferraro MF, Moreno AS, Castelli EC, et al. A single nucleotide deletion at the C1 inhibitor gene as the cause of hereditary angioedema: insights from a Brazilian family. Allergy 66:1384-1390, 2011.
3. Agostoni A, and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206-215, 1992.
4. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
5. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31:407-414, 2010.
6. Frank MM, Gelfand JA, and Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 84:580-593, 1976.
7. Kaplan AP, and Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 104:193-204, 2010.
8. Zuraw BL. HAE therapies: past present and future. Allergy Asthma Clin Immunol 6:23, 2010.
9. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol 100(1 Suppl 2):S30-S40, 2008.
10. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 139:379-394, 2005.
11. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of pa- tients with angioedema. J Allergy Clin Immunol 106:1147-1154, 2000.
12. Füst G, Farkas H, Csuka D, et al. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 41:256-262, 2011.
13. Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 284:2-9, 1982.
14. Riedl M, Gower RG, and Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol 106:316-322, 2011.
15. Bork K, Bygum A, and Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153-161, 2008.
16. Cinryze [package insert]. Exton, PA: ViroPharma Biologics, Inc.; viropharma.com/physicians/cinryze%20overview/cinryze%20package%20insert.aspx; 2010.
17. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513-522, 2010.
18. Zuraw B, Baker J, Hurewitz D, et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Abstract Book of the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology, Phoenix, AZ, November 11-16, 2010, A100 (Abs 262).
19. Berinert [package insert]. Marburg, Germany: CSL Behring GmbH; www.berinert.com/professional/prescribinginformation.aspx; 2009.
20. Cetor [package insert]. Amsterdam, The Netherlands: Sanquin; www.sanquin.nl/repository/documenten/en/prod-en-dienst/plasmaproducten/139660/ Package-Leaflet.pdf; 2010.
21. Morgan BP. Hereditary angioedema: therapies old and new [published correction appears in N Engl J Med 363:2673, 2010]. N Engl J Med 363:581-583, 2010.
22. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, et al. On demand treatment and home therapy of hereditary angioedema in Germany: the Frankfurt experience. Allergy Asthma Clin Immunol 6:21, 2010.
23. Bygum A, Andersen KE, and Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19:147-151, 2009.
24. Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 102:366-372, 2009.